Generic Pliaglis Availability
Last updated on Apr 10, 2025.
Pliaglis is a brand name of lidocaine/tetracaine topical, approved by the FDA in the following formulation(s):
PLIAGLIS (lidocaine; tetracaine - cream;topical)
-
Manufacturer: CRESCITA THERAP
Approval date: June 29, 2006
Strength(s): 7%;7% (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pliaglis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Solid-forming local anesthetic formulations for pain control
Patent 10,350,180
Issued: July 16, 2019
Inventor(s): Zhang Jie
Assignee(s): Crescita Therapeutics Inc.Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.
Patent expiration dates:
- January 14, 2031✓
- January 14, 2031
-
Solid-forming local anesthetic formulations for pain control
Patent 10,603,293
Issued: March 31, 2020
Inventor(s): Zhang Jie
Assignee(s): Crescita Therapeutics Inc.Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.
Patent expiration dates:
- January 14, 2031✓
- January 14, 2031
-
Solid-forming topical formulations for pain control
Patent 10,751,305
Issued: August 25, 2020
Inventor(s): Zhang Jie & Hull Wade & Vo Ngoc Truc-Chi
Assignee(s): Crescita Therapeutics Inc.Solid-forming topical formulations can include a local anesthetic, an emulsifying agent, polymer, and water. The formulation can include from 0.1 wt % to 5 wt % more of the emulsifying agent, from 0.1 wt % to 20 wt % more of the polymer, and from 0.1 wt % to 30 wt % more water than a comparative formulation, and drying time is faster than the comparative formulation when applied to a skin surface and dried under the same ambient conditions.
Patent expiration dates:
- January 14, 2031✓
- January 14, 2031
More about Pliaglis (lidocaine / tetracaine topical)
- Pliaglis consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: topical anesthetics
- En español
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.